 Connection
Charles Dinarello to Immunoglobulin G
This is a "connection" page, showing publications Charles Dinarello has written about Immunoglobulin G.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.545 |
|
|
|
-
Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl. 2005 Mar; 74:40-7.
Score: 0.182
-
Shirey KA, Lai W, Patel MC, Pletneva LM, Pang C, Kurt-Jones E, Lipsky M, Roger T, Calandra T, Tracey KJ, Al-Abed Y, Bowie AG, Fasano A, Dinarello CA, Gusovsky F, Blanco JC, Vogel SN. Novel strategies for targeting innate immune responses to influenza. Mucosal Immunol. 2016 09; 9(5):1173-82.
Score: 0.097
-
Lee S, Lee Y, Hong K, Hong J, Bae S, Choi J, Jhun H, Kwak A, Kim E, Jo S, Dinarello CA, Kim S. Effect of recombinant a1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes. Mol Med. 2013 May 20; 19:65-71.
Score: 0.081
-
Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R, Lubberts E, Dinarello CA, van Den Berg WB, Chvatchko Y. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest. 2001 Dec; 108(12):1825-32.
Score: 0.036
-
Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 1997 Mar; 15(3):1052-62.
Score: 0.026
-
Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res. 1996 Aug; 2(8):1341-51.
Score: 0.025
-
Pereira BJ, Poutsiaka DD, King AJ, Strom JA, Narayan G, Levey AS, Dinarello CA. In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int. 1992 Dec; 42(6):1419-24.
Score: 0.019
-
Barak V, Peritt D, Flechner I, Yanai P, Halperin T, Treves AJ, Dinarello CA. The specific IL-1 inhibitor from the human M20 cell line is distinct from the IL-1 receptor antagonist. Lymphokine Cytokine Res. 1991 Dec; 10(6):437-42.
Score: 0.018
-
Keane WF, Hirata-Dulas CA, Bullock ML, Ney AL, Guay DR, Kalil RS, Dinarello CA, Halstenson CE, Peterson PK. Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure. J Am Soc Nephrol. 1991 Oct; 2(4):841-7.
Score: 0.018
-
Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood. 1991 Sep 01; 78(5):1275-81.
Score: 0.018
-
Jandl RC, George JL, Dinarello CA, Schur PH. The effect of interleukin 1 on IgG synthesis in systemic lupus erythematosus. Clin Immunol Immunopathol. 1987 Dec; 45(3):384-94.
Score: 0.014
-
Banda NK, Vondracek A, Kraus D, Dinarello CA, Kim SH, Bendele A, Senaldi G, Arend WP. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol. 2003 Feb 15; 170(4):2100-5.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|